On 16 April 2018, orphan designation (EU/3/18/2013) was granted by the European Commission to Roche Registration Limited, United Kingdom, for polatuzumab vedotin for the treatment of diffuse large B-cell lymphoma.
The sponsorship was transferred to Roche Registration GmbH., Germany, in July 2018.
Polatuzumab vedotin has been authorised in the EU as Polivy since 16 January 2020.
|Disease / condition||
Treatment of diffuse large B-cell lymphoma
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.